ArticleBMC nephrology2026
Predictive role and clinical correlation of copeptin in patients with type 2 diabetes mellitus associated nephropathy approaching end-stage renal disease.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relationship between apolipoprotein A levels and chronic kidney disease stage 4-5 in Chinese type 2 diabetes participants.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic Kidney Disease (DKD) is the leading cause of End Stage Renal Disease (ESRD). Arginine Vasopressin (AVP) plays pivotal roles in osmoregulation and renal water conservation. As patients with DKD are prone to develop osmotic irregularities, AVP is therefore, a potential pathophysiological target for disruption. Copeptin, a surrogate marker of AVP, is preferred over AVP due to comparatively greater stability and longer half-life. The study is designed to correlate the copeptin levels among subjects with Type 2 Diabetes Mellitus (DM) with worsening renal outcomes.
methodsIt was a comparative cross-sectional study on 120 subjects with T2DM who were stratified into progressive deteriorating stages of chronic kidney disease (CKD) as per NKF KDOQI guidelines. Different biochemical variables HbA1c, serum BUN, serum creatinine UACR and GFR were done from the affiliated lab. Serum copeptin levels were determined using Copeptin sandwich ELISA technique. Data was analyzed through Statistical Program for Social Sciences (SPSS).
resultsOut of the 120 subjects that were recruited for study, 30% of subjects (n = 36) developed severely decreased kidney function with GFR less than 30mL/min/1.73m2. Copeptin levels were seen to be increased with progressive stages of albuminuria (175.8 ± 148.4 pg/ml, 221.2 ± 213.1 pg/ml and 385.3 ± 288.4 pg/ml at UACR stage 1, 2 and 3, respectively) with positive correlation i.e. r = 0.375, p = ≤ 0.001. It was also found to be negatively correlated with declining GFR i.e. from 195.8 ± 174.1 pg/ml at stage 1 CKD to 291.7 ± 268.8 pg/ml at stage 5 CKD (r = -0.409, p = ≤ 0.001).
conclusionsIncrease in serum copeptin levels from stage 1 to stage 5 of CKD suggest its predictive role in T2DM associated nephropathy, supporting its potential role as an early biomarker. Early detection may help delay ESRD progression through timely interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.